The three CYBA variants (rs4673, rs1049254 and rs1049255) are benign: new evidence from a patient with CGD

Area of Science:

• Immunology
• Genetics
• Molecular Biology

Background:

• Chronic granulomatous disease (CGD) is an inherited immunodeficiency characterized by NADPH oxidase deficiency.
• Mutations in CYBB or CYBA genes impair NADPH oxidase function, affecting reactive oxygen species generation.
• Previous research suggested a CYBA haplotype associated with reduced reactive oxygen species, necessitating further validation.

Purpose of the Study:

• To confirm the benign nature of three specific CYBA gene variants (rs4673, rs1049254, rs1049255).
• To identify and report a novel mutation in the CYBB gene associated with CGD.

Main Methods:

• Flow cytometry was used to analyze neutrophil NADPH oxidase activity and gp91phox protein expression.
• Direct sequencing of the CYBB and CYBA genes was performed on a patient with CGD and family members.
• Clinical and immune phenotypes were assessed for CGD diagnosis.

Main Results:

• A patient was diagnosed with CGD based on clinical and immune findings.
• A novel homozygous mutation in the CYBB gene was identified in the patient.
• The identified CYBB mutation was confirmed as pathogenic, while the three CYBA variants were confirmed as benign.

Conclusions:

• The study reports a novel pathogenic mutation in the CYBB gene responsible for CGD.
• The findings confirm that the three investigated CYBA gene variants are benign and do not contribute to CGD pathogenesis.
• This research contributes to the genetic understanding of CGD and aids in accurate genetic diagnostics.